Article ID Journal Published Year Pages File Type
5675515 Virus Research 2017 9 Pages PDF
Abstract

•The Illumina MiSeq currently has the most favorable parameters for HIV resistance genotype testing by next-generation sequencing.•The extensive genetic variability of HIV within hosts is a key challenge for next-generation sequence analysis.•The MiSeq system has exhibited both significant longitudinal (between run) and within-run cross-contamination issues.•The high throughput of the MiSeq provides an opportunity for cost-saving by processing hundreds of samples on the same run.

Genetic sequencing (“genotyping”) plays a critical role in the modern clinical management of HIV infection. This virus evolves rapidly within patients because of its error-prone reverse transcriptase and short generation time. Consequently, HIV variants with mutations that confer resistance to one or more antiretroviral drugs can emerge during sub-optimal treatment. There are now multiple HIV drug resistance interpretation algorithms that take the region of the HIV genome encoding the major drug targets as inputs; expert use of these algorithms can significantly improve to clinical outcomes in HIV treatment. Next-generation sequencing has the potential to revolutionize HIV resistance genotyping by lowering the threshold that rare but clinically significant HIV variants can be detected reproducibly, and by conferring improved cost-effectiveness in high-throughput scenarios. In this review, we discuss the relative merits and challenges of deploying the Illumina MiSeq instrument for clinical HIV genotyping.

Related Topics
Life Sciences Immunology and Microbiology Virology
Authors
, ,